Incidence, causative drugs, and economic consequences of drug-induced SJS, TEN, and SJS–TEN overlap and potential drug–drug interactions during treatment: a retrospective analysis at an Indonesian referral hospital

Rizky Abdulah¹ Tazkia F Suwandiman¹ Nadhira Handayani¹ Dika P Destiani¹ Auliya A Suwantika¹ Melisa I Barliana² Keri Lestari¹

¹Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, ²Department of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Indonesia

Background: Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acute life-threatening adverse drug reactions (ADRs) that are commonly caused by medications. Apart from their contribution to morbidity and mortality, these diseases may also present substantial consequences on health care resources. In this study, we aimed to identify the incidence, causative drugs, and economic consequences of these serious ADRs and potential drug–drug interactions (DDIs) during treatment.

Methods: A retrospective study that included 150 patients diagnosed with drug-induced SJS, SJS–TEN overlap, and TEN, from 2009 to 2013 in a referral hospital in West Java Province, Indonesia, was conducted to analyze the causative drugs, cost of illness (COI) as a representation of economic consequences, and potential DDIs during treatment.

Results: The results showed that analgesic–antipyretic drugs were the most frequently implicated drugs. The COIs for SJS, SJS–TEN overlap, and TEN patients were 119.49, 139.21, and 162.08 US dollars per day, respectively. Furthermore, potential DDIs with several therapeutic medications and corticosteroids used to treat SJS, SJS–TEN overlap, and TEN were also identified.

Conclusion: This study showed that analgesic–antipyretic was the major causative drug which contributed to SJS, SJS–TEN overlap, and TEN. Furthermore, our results also showed that SJS, SJS–TEN overlap, and TEN may cause considerable financial consequences to patients.

Keywords: Stevens–Johnson syndrome, toxic epidermal necrolysis, adverse drug reactions, cost of illness

Introduction

Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acute life-threatening adverse drug reactions (ADRs) characterized by epidermal detachment and mucositis.¹ The basic difference between SJS and TEN is the percentage of body surface affected, and SJS affects <10% of the body surface, SJS–TEN overlap involves 10%–30% of the body surface, and TEN affects >30% of the body surface area.² ³ The incidence varies from 1 to 6 cases and 0.4 to 1.2 cases per million annually for SJS and TEN, respectively.⁴–⁶ However, the incidence is higher among people living with HIV/AIDS.⁷
Drugs are identified as the main etiologic agents of SJS, TEN, and SJS–TEN overlap syndrome. Based on RegisSCAR/EuroSCAR registries, the highest risk drugs include allopurinol, carbamazepine, cotrimoxazole, and other anti-infective sulfonamides, sulfasalazine, lamotrigine, nevirapine, oximac-type non-steroidal anti-inflammatory drugs (NSAIDs), phenobarbital, and phenytoin. Moderate-risk drugs include cephalosporins, macrolides, quinolones, tetracyclines, and acetic acid-type NSAIDs. Low-risk drugs, that in previous studies, were not associated with a measurable risk, including beta-blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, sulfonamide-based thiazide diuretics, sulfonyleurea anti-diabetics, insulin, and propionic acid–type NSAIDs.5,6

Despite the fact that the incidence of SJS or TEN is acute life-threatening, the condition may also lead to significant financial consequences for the patients.10 Therefore, identification and withdrawal of drugs suspected to cause SJS or TEN are important.11 In Indonesia, however, little work has been conducted to identify the prevalence, causative drugs, and economic consequences caused. Accordingly, it is important to explore the best strategy to find as many relevant studies as possible. Thus, this study was aimed to identify the number of incidence, causative drugs, economic consequences, and potential drug–drug interaction (DDI) during treatment of these serious ADRs.

Methods
Data collection and study populations
We conducted a retrospective study in a referral hospital in West Java Province, the most populous Indonesian province, that is covered with 46.7 million population.12 Medical records from patients diagnosed with drug-induced SJS (ICD10 code L50.1), TEN (L50.2), or SJS–TEN overlap (L50.3) syndrome from January 1, 2009, to December 31, 2013, were recalled and included in the study. A data collection sheet was designed for the purpose of organizing collected data from patient records. Data included patient demographics, disease progression, duration of hospital stay, detailed treatment regimen, and suspected causative drugs as specifically mentioned in medical records by treating physicians. Incomplete patient records and records of patients referred with SJS, TEN, or SJS–TEN overlap syndrome from other hospitals were excluded from the study. Incomplete patient records that excluded were due to insufficient data and improper record, that is missing of suspected causative drug from the treating physicians, and incomplete medical treatment records. Two authors (RA and DPD) independently assessed the medical record for inclusion to the study. Differences were discussed and consensus reached.

Ethical approval for the study was obtained from the Ethical Committee for Health Research of Hasan Sadikin Hospital, Bandung, Indonesia No: LB.04.01/A05/EC/536/XII/2014. The study was conducted according to the guidelines of the Declaration of Helsinki. Written informed consent was not required because this was a retrospective observational study. No medical interventions were performed during the study. All ethical considerations were followed. Patient files were processed anonymously. No personal data were collected.

Analysis of economic consequences
The economic consequences of SJS, TEN, and SJS–TEN overlap were calculated using cost of illness (COI) for each patient. A societal perspective was applied in this study by considering the total direct medical cost and indirect cost of lost productivity. The direct medical cost was calculated by considering the price of all medications received, expenses (preparation and administrative costs, monitoring costs, and the costs of treatment for adverse events and treatment failures), the cost of action, and the hospital room rate (including fees for doctors, nurses, pharmacies, and nutritionists that differ depending on the severity and treatment received by each patient). The potential loss of productivity was calculated using a report from the Indonesian Statistical Agency for average monthly income of people living in Bandung City, Indonesia,13 that adjusted to the total length of hospital stay of each patient.

Currency was converted from the Indonesian rupiah (IDR) to the US dollar (USD) using the World Bank’s purchasing power parity (PPP) conversion factor, which is the number of units of a country’s currency required to buy the same amount of goods and services in the domestic market as the USD would buy in the USA.14

Analysis of drug interaction
The analysis of potential DDIs was performed to analyze the interactions of SJS/TEN treatment with the drugs suspected of being the cause of SJS/TEN and interactions of concomitant therapy between SJS/TEN treatment with drugs used to treat the original disease not related to SJS/TEN. Identification of DDIs was performed with Truven Health Analytics Micromedx®, a registered subscription database, and Drugs.com™ and Medscape.com™, 2 free databases. Micromedx provides reference information for drug management for diseases and conditions, as well as toxicology and patient education. Micromedx
identifies potential DDIs, including the mechanism of DDIs, potential adverse reactions, their clinical consequences, and level of documentation available for the interaction (excellent: controlled study have clearly established; good: documentation strongly suggests the interactions; fair: available documentation were poor). Drugs.com is a free database powered by Wolters Kluwer Health, the American Society of Health-System Pharmacists, Cerner Multum, and Micromedex, which are leading medical information databases. Medscape.com provides online medical information and educational tools, including a drug interaction checker.

**Results**

**Number of incidence**

From the records of 150 patients diagnosed with SJS, SJS–TEN overlap, and TEN during 2009–2013, a total of 101 medical records were included in this study. The details of the selection process are shown in Figure 1. The demographics of the patients included in this study are shown in Table 1.

**Economic consequences**

The total economic loss from the 101 cases of SJS, SJS–TEN overlap, and TEN during the study period was estimated at 131,763.82 USD, including 77,786.64, 29,179.29, and 24,797.89 USD from SJS, SJS–TEN overlap, and TEN, respectively. For SJS, SJS–TEN overlap, and TEN, the average cost per patient was 1,111.24, 1,823.71, and 1,653.12 USD, respectively, and the average direct cost per patient was 974.86, 1,630.91, and 1,504.07 USD, respectively. A detailed breakdown of the cost calculation and average spending per patient per day for SJS, SJS–TEN overlap, and TEN can be seen in Table 2.

**Causative drugs**

Each drug implicated in SJS, SJS–TEN overlap, and TEN in the study can be seen in Table 3. As shown, analgesic–antipyretic drugs (acetaminophen) were reported most frequently, followed by antibiotics (amoxicillin, cotrimoxazol, and ciprofloxacin), tuberculosis drugs (rifampicin, ethambutol, isoniazid, and pyrazinamide), anti-HIV medications (nevirapine, lamivudine, and zidovudine), and NSAIDs (mefenamic acid, ibuprofen, and aspirin). In Table 3, the implicated drugs were compared to other reports from Japan, Europe and Israel, France, sub-Saharan Africa, and Senegal.

**Potential DDIs**

The results of DDI analysis from 3 of the databases showed discrepancies in the classification of severity and mechanism of interaction (Table 4A and B). However, we found 29 cases identified by all 3 databases for potential interactions of SJS/TEN treatment with the drugs suspected of being the cause of SJS/TEN and 87 cases identified by all 3 databases for potential interaction of concomitant therapy between SJS/TEN treatment with drugs used to treat the original disease not related to SJS/TEN. The most common potential DDIs of corticosteroids with the drugs suspected of being the cause of SJS/TEN identified by the 3 databases were dexamethasone–rifampicin (24.14%), dexamethasone–ciprofloxacin (20.69%), dexamethasone–ibuprofen (20.69%), dexamethasone–mefenamic acid (17.24%), and dexamethasone–aspirin (10.34%). Meanwhile, the most common potential DDIs of concomitant treatment of corticosteroids with drugs used to treat the original disease not related to SJS/TEN were dexamethasone–ofloxacin (12.64%), dexamethasone–levofoxacin (10.34%), dexamethasone–ciprofloxacin (8.05%), dexamethasone–efavirenz (6.90%), and dexamethasone–phenobarbital (6.90%).

**Discussion**

The drugs most frequently implicated in cases of SJS, SJS–TEN overlap, and TEN in our study were analgesic–antipyretic...
Although not in the top 5 of drugs most implicated in this study, antiepileptic carbamazepine counted for up to 3.92% of all the drugs implicated. Carbamazepine-induced SJS/TEN is reported to be associated with HLA allele B*1502,22 whose frequency has been reported to be as high as 11.6% in Western Javanese population.21 Therefore, this should also be seriously considered, especially as carbamazepine also used in off-label prescription.

It has been reported that the treatment of ADR-related diseases requires substantial financial resources, as many countries may spend 15%–20% of hospital budgets for this purpose.25,26 Considering the potentially serious consequences, SJS, SJS–TEN overlap, and TEN may have a significant clinical and economic impact on patients. A previous study reported that patients with ADRs may stay in the hospital 12 days longer than those without ADRs.27 This can significantly affect those in developing countries due to the damaging effects of ADR-related diseases on the socioeconomic progress of those countries. SJS, SJS–TEN overlap, and TEN will increase treatment costs due to prolonged hospital stays, additional clinical investigations, and treatments. As seen in Table 2, the COI of SJS patients in our study was 119.49 USD per day for only SJS-related medication, not the cost of treatment of their primary diagnosis before SJS diagnosis. Meanwhile, with involvement of more body surface area, the daily COI for SJS–TEN overlap and TEN patients increases to 139.21 and 162.08 USD, respectively. These are higher than a previous report from Gujarat, India, that reported 15.16, 18.04, and 22.96 USD per day for SJS, SJS–TEN overlap, and TEN, respectively, after converted to USD using the World Bank’s PPP conversion factor.10,14 The Gujarat study, however, only calculated the cost of medications, diagnosis, and consumables used during the hospital stay.

The average hospital stay in this study was ~9.3, 13.1, and 10.2 days for SJS, SJS–TEN overlap, and TEN, respectively. The number of hospital stays may associate to the different levels of severity and complexity of SJS, SJS–TEN overlap, and TEN patients. Patients with TEN have a more severe disease and are likely to have longer hospital stay than patients with SJS. However, these findings were less significant than those reported in a previous study in Thailand.28 In particular, a longer hospital stay was observed among SJS–TEN patients than among TEN patients in our study. This finding could be explained by the fact that 8 of 15 TEN patients were died within a short period of time, thus resulting in a shorter average hospital stay than SJS–TEN patients. This result is in line with the latest study from Thailand.29 In contrast to the average hospital stay in this study, TEN patients had the highest COI of the patients studied. This result is probably because TEN patients were likely to be more complicated recoveries than SJS and SJS–TEN patients.

There is currently no specific treatment for TEN or SJS because of their complex pathogenesis. Although systemic corticosteroids and intravenous immunoglobulin are controversial, they are still the main treatment methods in many countries,30 including Indonesia. In our study, most cases were treated with corticosteroids. Although corticosteroids are controversial for the treatment of SJS and TEN due to the reports on the increased risk of secondary infection and delay in epithelialization,31,32 they are still beneficial when started early and in an appropriate dose range.33 The use of corticosteroids may be based on the idea that they may inhibit immunological responses by suppressing interferon gamma-mediated apoptosis and the functions of cytotoxic T lymphocytes.34 The corticosteroids, however, have to be used cautiously for the treatment of SJS, SJS–TEN overlap, and TEN, as in our study, they have the potential for DDIs with medicines used to treat the primary disease. The most common potential DDIs of corticosteroids found in this

### Table 1 Demographic characteristics of patients included in this study

| Demographic parameters | SJS (n=70) | SJS–TEN overlap (n=16) | TEN (n=15) |
|------------------------|------------|-----------------------|------------|
| Gender                 |            |                       |            |
| Male                   | 33         | 8                     | 5          |
| Female                 | 37         | 8                     | 10         |
| Age (years)            | 30.15±16.45| 26.75±18.65           | 25.45±15.82|
| LoS (days)             | 9.33±6.68  | 13.19±6.91            | 10.20±7.66 |

Note: Data presented as number or mean ± SD.

Abbreviations: SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; LoS, length of hospital stay.

### Table 2 Economic cost calculation and average spending per patient per day for each case of SJS, SJS–TEN overlap, and TEN in this study

|                      | SJS         | SJS–TEN overlap | TEN         |
|----------------------|-------------|-----------------|-------------|
| Length of hospital stay (days) | 9.3         | 13.1            | 10.2        |
| Direct medical cost   |             |                 |             |
| Prescribed medicine related to SJS, SJS–TEN overlap, and TEN treatment (USD) | 163.04      | 280.49          | 279.39      |
| Medical treatment cost (USD) | 117.32      | 249.17          | 284.07      |
| Other medical supporting cost (USD) | 216.39      | 426.85          | 418.25      |
| Hospital stay and administration (USD) | 478.11      | 674.40          | 522.37      |
| Indirect medical cost  |             |                 |             |
| Potential productivity lost (USD) | 136.38      | 192.80          | 149.12      |
| Total COI (USD)       | 1,111.24    | 1,823.71        | 1,653.20    |
| COI per day of hospital stay (USD) | 119.49      | 139.21          | 162.08      |

Abbreviations: SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; USD, US dollar; COI, cost of illness.
### Table 3: Drugs implicated in SJS, SJS–TEN overlap, and TEN, their incidence in this study, and comparison with other reports

| Drugs implicated | Our study | Other reports |
|-----------------|-----------|---------------|
| | Indonesia (2009–2013) | Yamane et al, Japan (2000–2006) | Halevy et al, Europe and Israel (1997–2001) | Gueudry et al, France (1994–2002) | Saka et al, Africa (2000–2010) | Mame Thierno et al, Senegal (1995–2000) |
| | | | | | | |
| Total no of cases | 101 | 117 | 379 | 159 | 177 | 38 |
| SJS | 70 | 52 | 134 | 56 | 129 | 0 |
| SJS–TEN overlap | 16 | 0 | 136 | 59 | 11 | 0 |
| TEN | 15 | 65 | 109 | 44 | 37 | 38 |
| Death rate (%) | 10.9 | 4.2 | 21 | 18.9 | 12.4 | 60 |

**Note:** The “–” indicates that this reference only provided 4 types of drugs.

**Abbreviations:** SJS, Stevens–Johnson syndrome; TEN, toxic epidermal necrolysis; NSAIDs, non-steroidal anti-inflammatory drugs.

### Table 4: Results of DDI analysis of (A) corticosteroids with the drugs suspected of being the cause of SJS/TEN and (B) concomitant treatment of corticosteroids with drugs used to treat the original disease not related to SJS/TEN, identified using the Micromedex, Drugs.com, and Medscape.com websites

| DDI databases | Micromedex | Drugs.com | Medscape.com |
|---------------|------------|-----------|--------------|
| **(A)** | | | |
| Number of patients with potential DDI | 32 (31.68%) | 42 (41.58%) | 46 (45.54%) |
| Number of patients without potential DDI | 69 (68.32%) | 59 (58.42%) | 55 (54.46%) |
| Number of interactions | 35 | 46 | 54 |
| Severity | | | |
| Contraindicated | 0 | 0 | 0 |
| Major/serious | 17 (48.57%) | 6 (13.04%) | 19 (35.19%) |
| Moderate/significant | 18 (51.43%) | 40 (86.96%) | 35 (64.81%) |
| Minor | 0 | 0 | 0 |
| Mechanism | | | |
| Unknown | 12 (34.29%) | 30 (65.22%) | 17 (31.48%) |
| Pharmacokinetic | 8 (22.86%) | 16 (34.78%) | 33 (61.11%) |
| Pharmacodynamic | 11 (31.43%) | 0 | 4 (7.41%) |
| Pharmacokinetic/pharmacodynamic | 4 (11.43%) | 0 | 0 |
| Onset | | | |
| Delay (after 24 hours) | 18 (51.43%) | – | – |
| Rapid (until 24 hours) | 0 | – | – |
| Not specified | 17 (48.57%) | – | – |
| Documentation | | | |
| Excellent | 6 (17.14%) | – | – |
| Good | 17 (48.57%) | – | – |
| Fair | 12 (34.29%) | – | – |
| **(B)** | | | |
| Number of patients with potential DDI | 49 (48.51%) | 34 (33.66%) | 27 (26.73%) |
| Number of patients without potential DDI | 52 (51.49%) | 67 (66.34%) | 74 (73.27%) |
| Number of interactions | 113 | 250 | 268 |
| Severity | | | |
| Contraindicated | 0 | 0 | 0 |
| Major/serious | 25 (22.12%) | 52 (20.80%) | 9 (3.36%) |
| Moderate/significant | 79 (69.91%) | 126 (50.40%) | 179 (66.79%) |
| Minor | 9 (7.96%) | 72 (28.80%) | 80 (29.85%) |

(Continued)
Table 4 (Continued)

| Mechanism                          | Micromedex | Drugs.com | Medscape.com |
|-----------------------------------|------------|-----------|--------------|
| Unknown                           | 56 (49.56%)| 83 (33.20%)| 50 (18.66%)  |
| Pharmacokinetic                   | 36 (31.86%)| 86 (34.40%)| 153 (57.09%)|
| Pharmacodynamic                   | 21 (18.58%)| 77 (30.80%)| 64 (23.88%)  |
| Pharmacokinetic/pharmacodynamic  | 0          | 4 (1.60%)  | 1 (0.37%)    |

Onset
- Delay (after 24 hours): 72 (63.72%)
- Rapid (until 24 hours): 5 (4.42%)
- Not specified: 36 (31.86%)

Documentation
- Excellent: 48 (42.48%)
- Good: 31 (27.43%)
- Fair: 34 (30.09%)

Note: The “–” indicate Drugs.com and Medscape.com did not provide that data.

Abbreviations: DDI, drug–drug interaction; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.

study were its interaction with fluoroquinolone antibiotics, which may increase risk of tendinitis and tendon rupture, with phenobarbital, which may decrease the blood level and systemic effects of corticosteroids, and with fluconazole, which may increase the blood level and systemic effect of corticosteroids. Health care professionals should pay attention to this potential DDI during the treatment of SJS, SJS–TEN overlap, and TEN, as it will increase the financial burden of the patients that was already high due to these serious ADRs.

Our study, however, still have some limitations. Due to the nature of retrospective study, we cannot recognize the ethnic origin of the subjects included in this study. Thus, we cannot analyze any potential association between SJS, SJS–TEN overlap, and TEN to specific ethnic of origin and populational variances among ADRs and DDIs. Furthermore, there is also potential bias in the SJS misclassification, as erythema multiforme major, a disease usually not related to medications and with much better prognosis, is also often classified as SJS. Although it was impossible to perform a retrospective reclassification, in our study we have minimized this misclassification bias by including only the drug-induced SJS in the study.

**Conclusion**

Treating physicians and pharmacists should also consider the potential DDIs between the medication given and the medication for other diseases that are independent from SJS, SJS–TEN overlap, and TEN treatments. Furthermore, our results also showed that SJS, SJS–TEN overlap, and TEN could present a considerable financial consequence to the patients.

**Acknowledgments**

The authors thank Truven Health Analytics for the access to Micromedex database. No sources of funding were used to assist in the preparation of this study.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Lee HY, Chung WH. Toxic epidermal necrolysis: the year in review. *Curr Opin Allergy Clin Immunol*. 2013;13(4):330–336.
2. Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. *J Dtsch Dermatol Ges*. 2009;7(2):142–160.
3. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. *J Am Acad Dermatol*. 2013;69(2):e171–e113.
4. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. *Arch Dermatol*. 1993;129(8):1059.
5. Rzany B, Mockenhaupt M, Stecker U, Hamouda O, Schopf E. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. *Arch Dermatol*. 1993;129(8):1059.
6. Naveen KN, Pai VV, Rai V, Athanikar SB. Retrospective analysis of Stevens Johnson syndrome and toxic epidermal necrolysis over a period of 5 years from northern Karnataka, India. *Indian J Pharmacol*. 2013;45(1):80–82.
7. Rzany B, Mockenhaupt M, Stecker U, Hamouda O, Schopf E. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. *Arch Dermatol*. 1993;129(8):1059.
8. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. *J Invest Dermatol*. 2008;128(1):35–44.
9. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. *Clin Pharmacol Ther*. 2010;88(1):60–68.
10. Barvialiya M, Sanmukhani J, Patel T, Paliwal N, Shah H, Tripathi C. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study. J Postgrad Med. 2011;57(2):115–119.

11. Garcia-Dovl I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136(3):323–327.

12. Indonesian Statistical Agency [webpage on the Internet]. Population and Gender by Regency and City in West Java Province 2015; 2015. Available from: http://jabar.bps.go.id/linkTableDinamis/view/id/12. Accessed October 15th, 2016.

13. Indonesian Statistical Agency. Updates on Indonesian Socio-Economics Main Indicator. Jakarta: Indonesian Statistical Agency; 2013.

14. The World Bank [webpage on the Internet]. PPP conversion factor, GDP (LCU per international $). Available from: http://data.worldbank.org/indicator/PA.NUS.PPP?pageNumber=2. Accessed July 1, 2015.

15. Ramos GV, Guaraldo L, Japiassu AM, Bozza FA. Comparison of two databases to detect potential drug-drug interactions between prescriptions of HIV/AIDS patients in critical care. J Clin Pharm Ther. 2015; 40(1):63–67.

16. Arenella C, Yox S, Eckstein DS, Ousley A. Expanding the reach of a cancer palliative care curriculum through web-based dissemination: a public-private collaboration. J Cancer Educ. 2010;25(3):418–421.

17. Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int. 2007;56(4):419–425.

18. Haley S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008; 58(1):25–32.

19. Gueudry J, Roujeau JC, Binaghi M, Soubrane G, Muraine M. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 2009;145(2):157–162.

20. Saka B, Barro-Traore F, Atadokpede FA, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries. Int J Dermatol. 2013;52(5):575–579.

21. Mame Thierno D, On S, Thierno Ndiate N, Ndiate B. Syndrome de Lyell au Sénégal: responsabilité de la thiacétazone [Lyell syndrome in Senegal: responsibility of thiacetazone]. Ann Dermatol Venereol. 2001;128(12):1305–1307. French.

22. Tangamornsukwan W, Chaiyakanpruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(9):1025–1032.

23. Yulwulandari R, Kashiwase K, Nakajima H, et al. Polymorphisms of HLA genes in Western Javanese (Indonesia): close affinities to Southeast Asian populations. Tissue Antigens. 2009;73(1):46–53.

24. Alrashood ST. Carbamazepine. Profiles Drug Subst Excip Relat Methods. 2016;41:133–321.

25. White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics. 1999;15(5):445–458.

26. Bordet R, Gauvier S, Le Louet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur J Clin Pharmacol. 2001;56(12):935–941.

27. Daviws EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009;4(2):e4439.

28. Roongpisuthipong W, Prompong S, Klangjareonchai T. Retrospective analysis of corticosteroid treatment in Stevens-Johnson Syndrome and/or toxic epidermal necrolysis over a period of 10 years in Vajira Hospital, Navaminrathiraj University, Bangkok. Dermatol Res Pract. 2014;2014:237821.

29. Dilokthornsakul P, Sawangjit R, Inprasong C, et al. Healthcare utilization and cost of Stevens-Johnson syndrome and toxic epidermal necrolysis management in Thailand. J Postgrad Med. 2016;62(2):109–114.

30. Sun J, Liu J, Gong QL, et al. Stevens-Johnson Syndrome and toxic epidermal necrolysis: a multi-aspect comparative 7-year study from the People’s Republic of China. Drug Des Devel Ther. 2014;8:2539–2547.

31. Kim PS, Goldfarb IW, Gaisford JC, Slater H. Stevens-Johnson syndrome and toxic epidermal necrolysis: a pathophysiological review with recommendations for a treatment protocol. J Burn Care Rehabil. 1983; 4(2):91–100.

32. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg. 1986;204(5):503–512.

33. Murphy JT, Purdue GF, Hunt JL. Toxic epidermal necrolysis. J Burn Care Rehabil. 1997;18(5):417–420.

34. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87(2):144–148.

35. Jagadeesan S, Sobhanakumari K, Sadanandan SM, et al. Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian J Dermatol Venereol Leprol. 2013;79(4):506–511.

36. Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003;36(11):1404–1410.

37. Stjernholm MR, Katz HF. Effects of diphenylhydantoin, phenobarbital, and diazemip on the metabolism of methylprednisolone and its sodium succinate. J Clin Endocrinol Metab. 1975;41(5):887–893.

38. Assan R, Fredj G, Larger E, Feutren G, Bismuth H. FK 506/fluconazole interaction enhances FK 506 nephrotoxicity. Diabete Metab. 1994;20(1):49–52.

39. Sinofsky FE, Pasquale SA. The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives. Am J Obstet Gynecol. 1998;178(2):300–304.

40. Hilbert J, Messig M, Kuye O, Friedman H. Evaluation of interaction between fluconazole and an oral contraceptive in healthy women. Obstet Gynecol. 2001;98(2):218–223.

41. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993; 129(1):92–96.